Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | DARA + pom-dex for R/R multiple myeloma

Sagar Lonial • 3 Jun 2019
ASCO 2019
Multiple Myeloma Daratumumab Dexamethasone Pomalidomide

Sagar Lonial, MD, FACP, from the Winship Cancer Institute, Druid Hills, GA, speaks at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL, discussing his research on the use of daratumumab, pomalidomide, and dexamethasone (DARA+ pom-dex) in the treatment of relapsed/refractory multiple myeloma.

More from Sagar Lonial

Practical advice for physicians treating patients with myeloma using belantamab mafodotin
0:37
Practical advice for physicians treating patients with myeloma using belantamab mafodotin
Sagar Lonial • 16 May 2025
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
1:08
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
Sagar Lonial • 16 May 2025
The ideal trial on the road to achieving the best outcome for patients with myeloma
0:41
The ideal trial on the road to achieving the best outcome for patients with myeloma
Sagar Lonial • 16 May 2025
The potential of CELMoDs for the treatment of multiple myeloma
0:50
The potential of CELMoDs for the treatment of multiple myeloma
Sagar Lonial • 16 May 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Sagar Lonial • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Sagar Lonial • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Sagar Lonial • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Sagar Lonial • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals